Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

Exclusion Criteria

• •1. Have an invasive malignancy, other than the disease under study.
• •2. Anticipated to require the use of a drain after radical prostatectomy.
• •3. Received any other anticancer therapy (e.g., including but not limited to chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy ) within 28 days.
• •4. History of allergic reactions attributed to compounds of similar chemical or biologic composition as those used in the STM-416p formulation including poloxamer 407 and sodium hyaluronate.
• •5. History of allogeneic organ transplant.
• •6. History of primary immunodeficiency.
• •7. QTc interval \>470 msec at Screening.